Reply
Marcus R. Pereira – 11 September 2015
Tackling the hepatitis C cost problem: A test case for tomorrow's cures
Rachel E. Simon, Steven D. Pearson, Chin Hur, Raymond T. Chung – 11 September 2015
Natural killer cell phenotype modulation and natural killer/T‐cell interplay in nucleos(t)ide analogue‐treated hepatitis e antigen‐negative patients with chronic hepatitis B
Carolina Boni, Pietro Lampertico, Lavinia Talamona, Tiziana Giuberti, Federica Invernizzi, Valeria Barili, Paola Fisicaro, Marzia Rossi, Maria Cristina Cavallo, Andrea Vecchi, Giuseppe Pedrazzi, Arianna Alfieri, Massimo Colombo, Gabriele Missale, Carlo Ferrari – 11 September 2015 – Natural killer (NK) and hepatitis B virus (HBV)‐specific T cells are functionally impaired in chronic hepatitis B (CHB).
Biology of hepatocyte regeneration in acute liver failure
Seth J. Karp – 5 September 2015
Mitogen‐activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial‐mesenchymal transition
Liu‐Xiao Yang, Qiang Gao, Jie‐Yi Shi, Zhi‐Chao Wang, Yong Zhang, Ping‐Ting Gao, Xiao‐Ying Wang, Ying‐Hong Shi, Ai‐Wu Ke, Guo‐Ming Shi, Jia‐Bin Cai, Wei‐Ren Liu, Meng Duan, Ying‐Jun Zhao, Yuan Ji, Dong‐Mei Gao, Kai Zhu, Jian Zhou, Shuang‐Jian Qiu, Ya Cao, Qi‐Qun Tang, Jia Fan – 4 September 2015 – The molecular pathogenesis of intrahepatic cholangiocarcinoma (iCCA) is poorly understood, and its incidence continues to increase worldwide.
Liver capsule: Validated and potential novel targets to treat hepatitis B virus
Barbara Testoni, Fabien Zoulim – 4 September 2015
Prognosis of acute variceal bleeding: Is being on beta‐blockers an aggravating factor? A short‐term survival analysis
Andrea Ribeiro de Souza, Vincenzo La Mura, Annalisa Berzigotti, Juan Carlos García‐Pagán, Juan G. Abraldes, Jaime Bosch – 4 September 2015 – Nonselective beta‐blockers (NSBB) are widely used because they have been proved effective in the prophylaxis of acute variceal bleeding (AVB). However, a significant proportion of patients still experience AVB while on treatment with NSBB, and its impact on prognosis of AVB is unknown.
Liver capsule: Validated and potential novel targets to treat hepatitis B virus
Barbara Testoni, Fabien Zoulim – 4 September 2015
Human immunodeficiency virus and liver disease: An update
Kenneth E. Sherman, Juergen Rockstroh, David Thomas – 4 September 2015 – Human immunodeficiency viral (HIV) infection affects approximately 1.2 million persons in the United States and 35 million worldwide. Progression to advanced liver disease remains a leading cause of death among HIV‐infected persons in the United States and elsewhere. Though mortality from HIV complications has been dramatically reduced wherever effective combination antiretroviral therapy is used, there has been little impact on liver‐related mortality.
Thrombelastography‐guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial
Lesley De Pietri, Marcello Bianchini, Roberto Montalti, Nicola De Maria, Tommaso Di Maira, Bruno Begliomini, Giorgio Enrico Gerunda, Fabrizio di Benedetto, Guadalupe Garcia‐Tsao, Erica Villa – 4 September 2015 – Bleeding is a feared complication of invasive procedures in patients with cirrhosis and significant coagulopathy (as defined by routine coagulation tests) and is used to justify preprocedure use of fresh frozen plasma (FFP) and/or platelets (PLT).